Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on Equity

Viking Therapeutics (VKTX) Equity Ratio (2016 - 2026)

Viking Therapeutics (VKTX) has disclosed Equity Ratio for 13 consecutive years, with 0.83 as the latest value for Q1 2026.

  • For Q1 2026, Equity Ratio fell 15.52% year-over-year to 0.83; the TTM value through Mar 2026 reached 0.83, down 15.52%, while the annual FY2025 figure was 0.89, 7.87% down from the prior year.
  • Equity Ratio hit 0.83 in Q1 2026 for Viking Therapeutics, down from 0.89 in the prior quarter.
  • Across five years, Equity Ratio topped out at 0.98 in Q1 2025 and bottomed at 0.83 in Q1 2026.
  • Average Equity Ratio over 5 years is 0.93, with a median of 0.96 recorded in 2025.
  • Year-over-year, Equity Ratio rose 9.65% in 2023 and then decreased 15.52% in 2026.
  • Viking Therapeutics' Equity Ratio stood at 0.86 in 2022, then increased by 9.65% to 0.95 in 2023, then rose by 2.5% to 0.97 in 2024, then dropped by 7.87% to 0.89 in 2025, then fell by 7.58% to 0.83 in 2026.
  • According to Business Quant data, Equity Ratio over the past three periods came in at 0.83, 0.89, and 0.96 for Q1 2026, Q4 2025, and Q3 2025 respectively.